Novo Nordisk A/S $NVO Shares Acquired by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 60.7% in the third quarter, HoldingsChannel.com reports. The firm owned 29,546 shares of the company’s stock after acquiring an additional 11,158 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,640,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in NVO. Agate Pass Investment Management LLC increased its holdings in Novo Nordisk A/S by 6.7% in the third quarter. Agate Pass Investment Management LLC now owns 8,819 shares of the company’s stock valued at $489,000 after buying an additional 550 shares in the last quarter. Bennett Selby Investments LP grew its holdings in shares of Novo Nordisk A/S by 8.7% in the 3rd quarter. Bennett Selby Investments LP now owns 55,696 shares of the company’s stock worth $3,091,000 after acquiring an additional 4,465 shares during the period. Country Club Bank increased its stake in Novo Nordisk A/S by 83.0% in the 3rd quarter. Country Club Bank now owns 49,360 shares of the company’s stock valued at $2,739,000 after purchasing an additional 22,394 shares in the last quarter. Beacon Financial Group raised its holdings in Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the last quarter. Finally, Cooper Financial Group acquired a new position in Novo Nordisk A/S during the third quarter worth $367,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $47.61 on Friday. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $104.75. The firm has a market cap of $212.59 billion, a price-to-earnings ratio of 13.84 and a beta of 0.67. The company’s 50-day moving average is $50.01 and its two-hundred day moving average is $57.86. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on NVO. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.